Amy Steele

Board Member

Amy is a caregiver and dedicated advocate within the PLGD community. Her daughter was diagnosed with Congenital Plasminogen Deficiency (PLGD) in June 2016 and subsequently participated in a six-year clinical trial for Ryplazim. Since then, Amy has been invited to share Regan’s story in support of advocacy and educational efforts across a variety of professional, clinical, and industry forums.

Her family’s experience—particularly the isolation and uncertainty they faced during her daughter’s diagnosis journey—became the foundation for her passion for advocacy and outreach. Amy’s mission is to ensure that no individual or family facing PLGD ever feels alone.